Company
ASX:NOX
Noxopharm Limited is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines. The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Sofra™ (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma™ (oncology).
93 stories · page 4 of 5
The clinical-stage drug development company’s collaboration with the US National Cancer Institute will run for an initial 12-month term, with the subsequent brain cancer program supported by a fully-costed budget.
The clinical-stage drug development company will team up with an arm of the National Institutes of Health as it investigates a new family of anti-cancer drugs.
The webinar will be livestreamed on the Proactive YouTube channel, where it can be viewed at any time following the event.
It now sees Veyonda having a major commercial future in the rapidly growing field of radioligand therapy, not just in prostate cancer, but across the broad cancer spectrum.
Noxopharm is studying its Veyonda® drug candidate across a wide range of medical disciplines, with activity pursued across its oncology, COVID-19, septic shock, chronic inflammatory and autoimmune diseases portfolio.
With a key regulatory approval in place, Noxopharm is a step closer to starting a multi-national trial on patients with progressive, metastatic prostate, breast or lung cancers using a higher dose of its Veyonda® drug candidate.
The clinical-stage drug development company believes, if a patent is granted, it will support its ambition to make Veyonda a standard of care drug in combination with major cancer therapies.
The Phase Two trial will broaden the scope of studies into a potential cancer treatment using a higher dose of its Veyonda® drug candidate.
The company is more than one drug – the business is a drug pipeline based on a novel technology platform that it sees meeting a range of unmet needs of key current interest to the global pharmaceutical industry.
Noxopharm welcomes this outcome given its recent LuPIN trial data showing even stronger survival outcome when Lu-PSMA-617 is combined with Veyonda®.
The key outcome of the World Association of Radiopharmaceutical and Molecular Therapy study is a median overall survival outcome of 11.6 months.
In Part 1 of the study, an 1800 milligram dose of Veyonda® was determined to be well tolerated in patients with compromised lung function.
CEP-2 will build on the encouraging outcomes of the CEP-1 pilot study where the chemo-enhancing effect of Veyonda was used to lower dosages of chemotherapy in patients with advanced solid cancers.
The aim of the CEP-1 study is to show that Veyonda boosts the effectiveness of conventional chemotherapy to allow the use of lower, safer dosages of chemotherapy.
The data supports the international patent application lodged on 30 March 2021, making the provisional patent a potentially very valuable commercial asset.
Compelling COVID-19 pre-clinical data showed idronoxil, the active ingredient in Veyonda, was effective in stopping cytokines, signalling molecules that regulate immune and inflammatory responses.
Nyrada was established in 2017 to advance the non-oncology assets developed by Noxopharm, leaving Noxopharm free to concentrate on the development of Veyonda.
The study provides proof-of-concept for well-tolerated chemotherapy with meaningful survival benefit.
Discovered a compound that is a potent inhibitor of IRAK4 protein which causes chronic inflammation including autoimmune diseases.
The company's shares are trading 6% higher intra-day, at $1.06.
